ants or Aspirin Study): a randomised trial. Lancet
2000;355:346-51.
143. Arnott C, Huang Y, Neuen BL, Di Tanna GL, Cannon CP, Oh R, et al.
The effect of canagliﬂozin on amputation risk in the CANVAS program and the CREDENCE trial. Diabetes Obes Metab 2020;22:
1753-66.
144. Davies MJ, Aroda VR, Collins BS, Gabbay RA, Green J, Maruthur NM,
et al. Management of hyperglycaemia in type 2 diabetes, 2022. A
consensus report by the American Diabetes Association (ADA) and
the European Association for the Study of Diabetes (EASD). Diabetologia 2022;65:1925-66.
145. Barraclough JY, Yu J, Figtree GA, Perkovic V, Heerspink HJL,
Neuen BL, et al. Cardiovascular and renal outcomes with canagliﬂozin in patients with peripheral arterial disease: Data from the
CANVAS Program and CREDENCE trial. Diabetes Obes Metab
2022;24:1072-83.
146. Xie P, Li Y, Deng B, Du C, Rui S, Deng W, et al. An explainable
machine learning model for predicting in-hospital amputation
rate of patients with diabetic foot ulcer. Int Wound J 2022;19:
910-8.
147. Ho VT, Gologorsky R, Kibrik P, Chandra V, Prent A, Lee J, et al. Open,
percutaneous, and hybrid deep venous arterialization technique for
no-option foot salvage. J Vasc Surg 2020;71:2152-60.
148. Shishehbor MH, Powell RJ, Montero-Baker MF, Dua A, MartínezTrabal JL, Bunte MC, et al. Transcatheter arterialization of deep veins
in chronic limb-threatening ischemia. New Engl J Med 2023